Table 2.
Time to a 2-point improvement in the WHO clinical progression scale, for the overall population and by care location, in the modified intention-to-treat population
|
Namilumab vs usual care |
Infliximab vs usual care |
|||
|---|---|---|---|---|
| Usual care group | Namilumab group | Usual care group | Infliximab group | |
| Overall | ||||
| Participants | 53 | 55 | 33 | 29 |
| Time, days | 10 (7–12) | 8 (6–9) | 10 (6–14) | 15 (6–21) |
| Ward | ||||
| Participants | 33 | 33 | 22 | 20 |
| Time, days | 9 (6–12) | 8 (5–10) | 9 (5–12) | 15 (5–NR) |
| ICU | ||||
| Participants | 20 | 22 | 11 | 9 |
| Time, days | 14 (5–NR) | 8 (6–11) | 14 (4–NR) | 19 (6–28) |
Data are n or median (95% CI). ICU=intensive care unit. NR=not recordable.